High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia multivorans

High-Dose Inhaled Nitric Oxide as Adjunct Therapy in Cystic Fibrosis Targeting Burkholderia multivorans

Background. Individuals with cystic fibrosis (CF) have persistent lung infections, necessitating the frequent use of antibiotics for pulmonary exacerbations. Some respiratory pathogens have intrinsic resistance to the currently available antibiotics, and any pathogen may acquire resistance over time...

Full description

Saved in:

Bibliographic Details
Main Authors:	Bethany L. Bartley, Kelly J. Gardner, Stefano Spina, Bryan P. Hurley, David Campeau, Lorenzo Berra, Lael M. Yonker, Ryan W. Carroll
Format:	Article
Language:	English
Published:	Wiley 2020-01-01
Series:	Case Reports in Pediatrics
Online Access:	http://dx.doi.org/10.1155/2020/1536714
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Genomics of an endemic cystic fibrosis Burkholderia multivorans strain reveals low within-patient evolution but high between-patient diversity.
by: Cédric Lood, et al.
Published: (2021-03-01)

Pulmonary microbial spectrum of Burkholderia multivorans infection identified by metagenomic sequencing
by: Hui Xu, et al.
Published: (2025-06-01)

Evaluating Obstructive Sleep Apnea Utilizing Arterial Tonometry in Individuals with Cystic Fibrosis
by: Michelle Chiu, et al.
Published: (2025-06-01)

Case report: Cervical suppurative lymphadenitis caused by burkholderia multivorans in a healthy child
by: Bei-bei Niu, et al.
Published: (2025-05-01)

Expression and Antagonistic Activity Against Plant Pathogens of the Phage Tail-like Protein from <i>Burkholderia multivorans</i> WS-FJ9
by: Tong-Yue Wen, et al.
Published: (2025-04-01)

Experience of the use of tobramycin for inhalation in children with cystic fibrosis
by: A. V. Orlov, et al.
Published: (2012-02-01)

Inhaled Nitric Oxide as an Adjunct to Thrombolytic Therapy in a Patient with Submassive Pulmonary Embolism and Severe Hypoxemia
by: Omesh Toolsie, et al.
Published: (2019-01-01)

Prerequisites for a dry powder inhaler for children with cystic fibrosis.
by: Anne J Lexmond, et al.
Published: (2017-01-01)

Burkholderia pseudomallei Infection in a Cystic Fibrosis Patient from the Caribbean: A Case Report
by: Dimas Mateos Corral, et al.
Published: (2008-01-01)

IFN-γ stimulates autophagy-mediated clearance of Burkholderia cenocepacia in human cystic fibrosis macrophages.
by: Kaivon Assani, et al.
Published: (2014-01-01)

Novel glycopolymer sensitizes Burkholderia cepacia complex isolates from cystic fibrosis patients to tobramycin and meropenem.
by: Vidya P Narayanaswamy, et al.
Published: (2017-01-01)

LUNG TRANSPLANTATION IN CYSTIC FIBROSIS PATIENT WITH CHRONIC AIRWAYS INFECTION OF BURKHOLDERIA CEPACIA (the first case in Russian Federation)
by: S. V. Gautier, et al.
Published: (2016-06-01)

Nasal nitric oxide levels in primary ciliary dyskinesia, cystic fibrosis and healthy children
by: Elif Güney, et al.
Published: (2019-02-01)

Inhaled nitric oxide: are expectations justified?
by: I. A. Kozlov
Published: (2024-12-01)

Short-term Tolerance to Inhaled Antibiotics in Patients With Bronchial Infection not Associated With Cystic Fibrosis
by: Luis Máiz, et al.
Published: (2025-07-01)

Burkholderia cepacia complex bacteremia outbreaks among non-cystic fibrosis patients in the pediatric unit of a university hospital
by: Sinan Tüfekci, et al.
Published: (2021-04-01)

Treatment with Inhaled Antibiotics as One of the Measures to Combat Bacterial Resistance (Cystic Fibrosis is Used as an Example)
by: A. V. Takhtamysheva
Published: (2024-03-01)

Eradication of Burkholderia cepacia Using Inhaled Aztreonam Lysine in Two Patients with Bronchiectasis
by: A. Iglesias, et al.
Published: (2014-01-01)

THE NATIONAL CONSENSUS PROJECT* «CYSTIC FIBROSIS: DEFINITION, DIAGNOSTIC CRITERIA, AND THERAPY». SECTION «INHALATION THERAPY» (ABRIDGED)
by: Ye. L. Amelina, et al.
Published: (2014-12-01)

In Vitro Inhibition of Neutrophil Elastase Activity by Inhaled Anti-Pseudomonas Antibiotics Used in Cystic Fibrosis Patients
by: Andreas Hector, et al.
Published: (2010-01-01)

Systemic organoprotection with inhaled nitric oxide (literature review)
by: I. A. Mandel, et al.
Published: (2024-08-01)

Production of Nitric Oxide and Expression of Inducible Nitric Oxide Synthase in Ovarian Cystic Tumors
by: Rosekeila Simões Nomelini, et al.
Published: (2008-01-01)

Beyond the inhaled nitric oxide in persistent pulmonary hypertension of the newborn
by: Mei-Yin Lai, et al.
Published: (2018-02-01)

Cystic Fibrosis in Asia
by: Shakil Ahmed, et al.
Published: (2020-01-01)

Clinical Experience in the Use of Inhaled Nitric Oxide in Infants with Pulmonary Hypertension
by: Robert P Lemke, et al.
Published: (1996-01-01)

Inhaled nitric oxide in adult patients with acute respiratory distress syndrome
by: José Ángel Monsalve-Naharro, et al.
Published: (2017-03-01)

Clinical Significance of Lung Microbiota and Experience of the Inhaled Antibacterial Therapy in Children of the Omsk Cystic Fibrosis Center (Сase Series)
by: Elena B. Pavlinova, et al.
Published: (2018-05-01)

Comprehensive In Vitro and In Silico Aerodynamic Analysis of High-Dose Ibuprofen- and Mannitol-Containing Dry Powder Inhalers for the Treatment of Cystic Fibrosis
by: Petra Party, et al.
Published: (2024-11-01)

Randomised cross-over trial evaluating the short-term effects of non-invasive ventilation as an adjunct to airway clearance techniques in adults with cystic fibrosis
by: Gemma Stanford, et al.
Published: (2019-10-01)

Scoping review of initiation criteria for inhaled nitric oxide in preterm infants (born
by: Hidehiko Nakanishi, et al.
Published: (2024-12-01)

New Treatment of Cystic Fibrosis
by: article Editorial
Published: (2020-01-01)

Burden of cystic fibrosis in children
by: Kathryn Bresnick, et al.
Published: (2021-01-01)

Pulmonary nontuberculous mycobacterial infections among women with cystic fibrosis and non-cystic fibrosis bronchiectasis
by: Jane E. Gross, et al.
Published: (2025-03-01)

Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis.
by: Nicha Wongjarupong, et al.
Published: (2025-01-01)

Effect of cystic fibrosis transmembrane conductance regulator modulators and dedicated cystic fibrosis gastrointestinal clinic visits on the incidence of distal intestinal obstructive syndrome in persons with cystic fibrosis
by: Nicha Wongjarupong, et al.
Published: (2025-01-01)

Inhaled Nitric Oxide Reverses Vascular and Respiratory Effects of ET-1 and PAF in Pigs
by: Mariangela Albertini, et al.
Published: (1994-01-01)

Pseudomonas aeruginosa ExoU augments neutrophil transepithelial migration.
by: Michael A Pazos, et al.
Published: (2017-08-01)

Oscillatory Shear Stress-Induced Arginase Activity May Explain Reduced Exhaled Nitric Oxide Levels after Vest Chest Physiotherapy in Cystic Fibrosis
by: Christoph Nowak
Published: (2014-01-01)

Mental disorders in patients with cystic fibrosis
by: A. A. Klimenko, et al.
Published: (2025-01-01)

Vitamin D Deficiency in Cystic Fibrosis
by: William B. Hall, et al.
Published: (2010-01-01)